Market News Latest

250+ Leading Acute Lymphocytic Leukemia Pipeline Companies are working to improve the Treatment Landscape

 Breaking News
  • No posts were found

250+ Leading Acute Lymphocytic Leukemia Pipeline Companies are working to improve the Treatment Landscape

February 02
21:16 2023
250+ Leading Acute Lymphocytic Leukemia Pipeline Companies are working to improve the Treatment Landscape

DelveInsight’s, “Acute Lymphocytic Leukemia Pipeline Insight, 2023,” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in Acute Lymphocytic Leukemia pipeline landscape. It covers the pipeline drug profiles, including Acute Lymphocytic Leukemia clinical trials and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Acute Lymphocytic Leukemia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Acute Lymphocytic Leukemia NDA approvals (if any), and product development activities comprising the technology, Acute Lymphocytic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Acute Lymphocytic Leukemia Pipeline Report

 

  • DelveInsight’s Acute Lymphocytic Leukemia pipeline report depicts a robust space with 250+ active players working to develop 250+ pipeline therapies for Acute Lymphocytic Leukemia treatment.

 

  • The leading Acute Lymphocytic Leukemia Companies includes PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Pinze Lifetechnology Co. Ltd., Celgene, and others.

 

  • Promising Acute Lymphocytic Leukemia Companies includes Uproleselan, SKLB1028, Pevonedistat, Orca T, Magrolimab, Iomab-B, Entospletinib, Nivolumab, ALT 803, BPX-501, TCB008, Tamibarotene, Pyronaridine, Trisenox (Arsenic Trioxide), NEI-01, MDG1011, OmnImmune, anti-FLT3 CAR-T, JNJ 63709178, IO 202, IDH 305, JSP 191, AB001, P-ckit-ALLO1, MP-0533, ALLO-316, ALL0-819, and others.

 

  • The Acute Lymphocytic Leukemia companies and academics are working to assess challenges and seek opportunities that could influence Acute Lymphocytic Leukemia R&D. The Acute Lymphocytic Leukemia pipeline therapies under development are focused on novel approaches to treat/improve Acute Lymphocytic Leukemia.

 

To explore more information on the latest breakthroughs in the Acute Lymphocytic Leukemia Pipeline treatment landscape of the report, click here @ Acute Lymphocytic Leukemia Pipeline Outlook

 

Acute Lymphocytic Leukemia Overview

Acute Lymphocytic Leukemia (ALL) (ALL) is also called acute lymphoblastic leukemia. “Acute” means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. “”Lymphocytic”” means it develops from early (immature) forms of lymphocytes, a type of white blood cell. ALL starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made). Most often, the leukemia cells invade the blood fairly quickly. They can also sometimes spread to other parts of the body, including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles (in males). Some cancers can also start in these organs and then spread to the bone marrow, but these cancers are not leukemia.

 

Recent Developments Activities in the Acute Lymphocytic Leukemia Treatment Landscape

  • In July 2016, Jazz Pharmaceuticals and Pfenex announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates.
  • In June 2018, Cellectis stated that the US Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a phase I clinical trial for UCART22.
  • In January 2023, Innate Pharma SA announced the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123.
  • In January 2023, the FDA granted JBI-802 orphan drug designation for patients diagnosed with small cell lung cancer (SCLC) and acute myeloid leukemia (AML), according to a press release from Jubilant Therapeutics.
  • In January 2022, Astex Pharmaceuticals, Inc. announced that the European Commission (EC) had granted orphan-drug designation (ODD) to the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML).

 

For further information, refer to the detailed Acute Lymphocytic Leukemia Unmet Needs, Mu Acute Lymphocytic Leukemia Market Drivers, and Acute Lymphocytic Leukemia Market Barriers, click here for Acute Lymphocytic Leukemia Ongoing Clinical Trial Analysis

 

Acute Lymphocytic Leukemia Emerging Drugs

 

CPX-351: Jazz Pharmaceuticals

Vyxeos (cytarabine and daunorubicin) liposome for injection, or CPX-351, is an investigational product being evaluated for the treatment of AML and is a combination of cytarabine and daunorubicin encapsulated within a nano-scale liposome at a 5:1 molar ratio. It is currently in phase II stage of development for ALL.

 

JZP-458: Jazz Pharmaceuticals

JZP-458 is being developed by Jazz Pharmaceuticals for the treatment of Acute Lymphoblastic Leukemia. It is currently in phase II/III stage of development.

 

UCART22: Cellectis

UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell stage of development through mature B-cells. CD22 expression occurs in more than 90% of patients with B-ALL. It is currently in phase I stage of development.

 

JZP-341: Jazz Pharmaceuticals

JZP-341 is being developed by Jazz Pharmaceuticals for the treatment of Acute Lymphoblastic Leukemia. It is currently in preclinical stage of development.

 

Acute Lymphocytic Leukemia Pipeline Therapeutics Assessment

There are approx. 250+ key companies which are developing the Acute Lymphoblastic Leukemia therapies. The Acute Lymphoblastic Leukemia companies which have their Acute Lymphocytic Leukemia (ALL) drug candidates in the most advanced stage, i.e. phase II/III include Jazz Pharmaceuticals and others.

 

Request a sample and discover the recent advances in Acute Lymphocytic Leukemia Ongoing Clinical Trial Analysis and Medications, click here @ Acute Lymphocytic Leukemia Treatment Landscape

 

Scope of the Acute Lymphocytic Leukemia Pipeline Report

 

  • Coverage- Global
  • Acute Lymphoblastic Leukemia Companies- PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Pinze Lifetechnology Co. Ltd., Celgene, and others.
  • Acute Lymphoblastic Leukemia Pipeline Therapies- Uproleselan, SKLB1028, Pevonedistat, Orca T, Magrolimab, Iomab-B, Entospletinib, Nivolumab, ALT 803, BPX-501, TCB008, Tamibarotene, Pyronaridine, Trisenox (Arsenic Trioxide), NEI-01, MDG1011, OmnImmune, anti-FLT3 CAR-T, JNJ 63709178, IO 202, IDH 305, JSP 191, AB001, P-ckit-ALLO1, MP-0533, ALLO-316, ALL0-819, and others.
  • Acute Lymphoblastic Leukemia Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Acute Lymphocytic Leukemia Market Drivers and Acute Lymphocytic Leukemia Market Barriers, click here @ Acute Lymphocytic Leukemia Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Acute Lymphocytic Leukemia (ALL): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Acute Lymphocytic Leukemia (ALL) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Acute Lymphocytic Leukemia (ALL) Collaboration Deals
  9. Late Stage Products (Phase III and Phase II/III)
  10. JZP-458: Jazz Pharmaceuticals
  11. Mid Stage Products (Phase II)
  12. CPX-351: Jazz Pharmaceuticals
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase I)
  15. UCART22: Cellectis
  16. Drug profiles in the detailed report…..
  17. Pre-clinical and Discovery Stage Products
  18. JZP-341: Jazz Pharmaceuticals
  19. Inactive Products
  20. Acute Lymphocytic Leukemia (ALL) Key Companies
  21. Acute Lymphocytic Leukemia (ALL) Key Products
  22. Acute Lymphocytic Leukemia (ALL)- Unmet Needs
  23. Acute Lymphocytic Leukemia (ALL)- Market Drivers and Barriers
  24. Acute Lymphocytic Leukemia (ALL)- Future Perspectives and Conclusion
  25. Acute Lymphocytic Leukemia (ALL) Analyst Views
  26. Acute Lymphocytic Leukemia (ALL) Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Acute Lymphocytic Leukemia Mergers and acquisitions, Acute Lymphocytic Leukemia Licensing Activities @ Acute Lymphocytic Leukemia Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services